{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:32:26Z","timestamp":1783467146814,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109207","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T01:31:14Z","timestamp":1662341474000},"page":"109207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis"],"prefix":"10.1016","volume":"112","author":[{"given":"Jin-Xian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Heng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cheng-Chung Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","article-title":"Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study","volume":"163","author":"Haroon","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0003319718814309","article-title":"The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis","volume":"70","author":"Bai","year":"2019","journal-title":"Angiology."},{"issue":"4","key":"10.1016\/j.intimp.2022.109207_b0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/acr.20364","article-title":"Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis","volume":"63","author":"Mathieu","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"10.1016\/j.intimp.2022.109207_b0020","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/ard.2005.050443","article-title":"Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis","volume":"65","author":"van Halm","year":"2006","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.109207_b0025","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3899\/jrheum.150316","article-title":"Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies","volume":"42","author":"Arida","year":"2015","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109207_b0030","article-title":"Uveitis as a risk factor for developing acute myocardial infarction in ankylosing spondylitis: a national population-based longitudinal cohort study","volume":"11","author":"Lai","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109207_b0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.autrev.2011.05.022","article-title":"Atherosclerosis in psoriatic arthritis","volume":"10","author":"Ramonda","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jbspin.2014.02.005","article-title":"Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study","volume":"81","author":"Ramonda","year":"2014","journal-title":"Joint Bone Spine."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.55563\/clinexprheumatol\/3qiqk3","article-title":"Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients","volume":"39","author":"Ortolan","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.109207_b0055","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.14315","article-title":"The effect of exercise training programs with aerobic components on C-reactive protein, erythrocyte sedimentation rate and self-assessed disease activity in people with ankylosing spondylitis: a systematic review and meta-analysis","author":"Harpham","year":"2022","journal-title":"Int J Rheum Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0060","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1756-185X.12347","article-title":"Aerobic capacity and its correlates in patients with ankylosing spondylitis","volume":"19","author":"Hsieh","year":"2016","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.intimp.2022.109207_b0065","doi-asserted-by":"crossref","unstructured":"M.F. Piepoli, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, M.T. Cooney, U. Corr\u00e0, B. Cosyns, C. Deaton, I. Graham, M.S. Hall, F.D.R. Hobbs, M.L. L\u00f8chen, H. L\u00f6llgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D.J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H.B. van der Worp, I. van Dis, W.M.M. Verschuren, S. Binno; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093\/eurheartj\/ehw106. Epub 2016 May 23. PMID: 27222591; PMCID: PMC4986030.","DOI":"10.1093\/eurheartj\/ehw106"},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0070","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int J Rheum Dis."},{"issue":"36","key":"10.1016\/j.intimp.2022.109207_b0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004792","article-title":"Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nationwide, population-based case-control study","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine (Baltimore)."},{"issue":"8","key":"10.1016\/j.intimp.2022.109207_b0080","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2018-213089","article-title":"Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis","volume":"77","author":"Dubreuil","year":"2018","journal-title":"Ann. Rheum Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0085","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10067-006-0396-x","article-title":"Plasma homocysteine status in patients with ankylosing spondylitis","volume":"26","author":"Wei","year":"2007","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/1756-185X.12986","article-title":"Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study","volume":"20","author":"Tam","year":"2017","journal-title":"Int J Rheum Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.109207_b0095","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.metabol.2007.05.009","article-title":"Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis","volume":"56","author":"Toussirot","year":"2007","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.intimp.2022.109207_b0100","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: testing and clinical relevance","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/heart.85.3.342","article-title":"Endothelial function and nitric oxide: clinical relevance","volume":"85","author":"Vallance","year":"2001","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/157016110790886965","article-title":"Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis","volume":"8","author":"Cugno","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trsl.2015.05.006","article-title":"Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis","volume":"167","author":"Shen","year":"2016","journal-title":"Transl Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0125","doi-asserted-by":"crossref","first-page":"100853","DOI":"10.1016\/j.cpcardiol.2021.100853","article-title":"Triggers of cardiovascular diseases in rheumatoid arthritis","volume":"47","author":"Zhang","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0130","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/rheumatology\/ket454","article-title":"Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?","volume":"53","author":"Tam","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study","volume":"20","author":"Lee","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"275","key":"10.1016\/j.intimp.2022.109207_b0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2018.10.024","article-title":"Ankylosing spondylitis: A novel risk factor for atrial fibrillation - A nationwide population-based study","volume":"15","author":"Moon","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials","volume":"5","author":"Curtis","year":"2019","journal-title":"RMD Open."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0000000000000053","article-title":"Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides","volume":"20","author":"Wasko","year":"2014","journal-title":"J. Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/ard.2005.035287","article-title":"Long term safety of etanercept in elderly subjects with rheumatic diseases","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/annrheumdis-2021-221001","article-title":"Fat mass and response to TNF\u03b1 blockers in early axial spondyloarthritis: an analysis of the DESIR cohort","volume":"81","author":"Molto","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.109207_b0165","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3390\/biom11101535","article-title":"Changes of metabolic biomarker levels upon one-year Anti-TNF-\u03b1 therapy in rheumatoid arthritis and ankylosing spondylitis: associations with vascular pathophysiology","volume":"11","author":"Cz\u00f3kolyov\u00e1","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0170","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3899\/jrheum.200916","article-title":"Soluble vascular biomarkers in rheumatoid arthritis and ankylosing spondylitis: Effects of 1-year antitumor necrosis Factor-\u03b1 therapy","volume":"48","author":"Pusztai","year":"2021","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-019-04497-0","article-title":"Effects of 1-year anti-TNF-\u03b1 therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"V\u00e9gh","year":"2020","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0180","doi-asserted-by":"crossref","first-page":"eAO4539","DOI":"10.31744\/einstein_journal\/2019AO4539","article-title":"Electrocardiographic changes in spondyloarthritis and use of anti-TNF-\u03b1 drugs: a retrospective study with 100 patients","volume":"17","author":"Longo","year":"2019","journal-title":"Einstein (Sao Paulo)"},{"issue":"4","key":"10.1016\/j.intimp.2022.109207_b0185","first-page":"185","article-title":"Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis","volume":"22","author":"Hatipsoylu","year":"2019","journal-title":"Anatol J Cardiol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109207_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220079","article-title":"Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study","volume":"14","author":"Hokstad","year":"2019","journal-title":"PLoS ONE"},{"issue":"27","key":"10.1016\/j.intimp.2022.109207_b0195","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011250","article-title":"Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-\u03b1 antagonists and healthy matched controls","volume":"97","author":"Zardi","year":"2018","journal-title":"Medicine (Baltimore)."},{"issue":"11","key":"10.1016\/j.intimp.2022.109207_b0200","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.numecd.2018.06.022","article-title":"Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases","volume":"28","author":"Schulte","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"270","key":"10.1016\/j.intimp.2022.109207_b0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijcard.2018.06.099","article-title":"Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases","volume":"1","author":"Ntusi","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0210","doi-asserted-by":"crossref","first-page":"13205","DOI":"10.1038\/s41598-018-31550-y","article-title":"Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment","volume":"8","author":"Batko","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0215","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-017-1439-1","article-title":"Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis","volume":"19","author":"Deyab","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169830","article-title":"Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"12","author":"Deyab","year":"2017","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.intimp.2022.109207_b0225","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s10067-017-3623-8","article-title":"Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNF\u03b1 therapy: association with predictors of cardiovascular risk","volume":"36","author":"Maia","year":"2017","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1756-185X.12608","article-title":"Assessment of serum asymmetric dimethylarginine levels and left ventricular diastolic function in patients with ankylosing spondylitis","volume":"20","author":"Inci","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0235","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13075-016-1148-1","article-title":"Effects of anti-TNF-\u03b1 treatment on lipid profile in rheumatic diseases: an analytical cohort study","volume":"18","author":"Hassan","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2022.109207_b0240","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3899\/jrheum.141532","article-title":"Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis","volume":"42","author":"Gkolfinopoulou","year":"2015","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109207_b0245","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3899\/jrheum.150193","article-title":"Reduction of inflammation drives lipid changes in ankylosing spondylitis","volume":"42","author":"Heslinga","year":"2015","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2013-203934","article-title":"Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis","volume":"74","author":"van Sijl","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2022.109207_b0255","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00296-015-3314-1","article-title":"Anti-TNF-\u03b1 therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients","volume":"35","author":"Genre","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0260","first-page":"640","article-title":"Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"32","author":"Genre","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109207_b0265","article-title":"IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy","volume":"671061","author":"Genre","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2022.109207_b0270","first-page":"798060","article-title":"Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect","author":"Genre","year":"2014","journal-title":"Mediators Inflamm."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0275","first-page":"218","article-title":"Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy","volume":"32","author":"Genre","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0280","first-page":"231","article-title":"Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"32","author":"Genre","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0285","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00394-013-0599-2","article-title":"CBT-506. TNF\u03b1 blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study","volume":"53","author":"Toussirot","year":"2014","journal-title":"Eur J Nutr."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0290","first-page":"913","article-title":"Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-\u03b1 therapy","volume":"31","author":"Genre","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0295","first-page":"749","article-title":"Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Genre","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109207_b0300","first-page":"538","article-title":"Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Miranda-Filloy","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109207_b0305","first-page":"532","article-title":"Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Genre","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0310","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/rheumatology\/ket469","article-title":"The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis\u2014a randomized, placebo-controlled pilot trial","volume":"53","author":"Tam","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.109207_b0315","doi-asserted-by":"crossref","unstructured":"I. Hmamouchi, C. Roux, S. Paternotte, S. Kolta, M. Dougados, K. Briot, Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-\u03b1 treatment. J Rheumatol. 41(6) (2014) 1112-7. doi:10.3899\/jrheum.131150. Epub 2014 Apr 15. Erratum in: J Rheumatol. 2014 Nov;41(11):2336. PMID: 24737911.","DOI":"10.3899\/jrheum.131150"},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/14397595.2013.843752","article-title":"Effects of infliximab treatment in terms of cardiovascular risk and insulin resistance in ankylosing spondylitis patients","volume":"24","author":"Ersozlu Bozkirli","year":"2014","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0325","first-page":"365","article-title":"Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Miranda-Filloy","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0330","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/kes272","article-title":"No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months","volume":"52","author":"Mathieu","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0335","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10067-013-2182-x","article-title":"NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study","volume":"32","author":"Moraes","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10067-012-2091-4","article-title":"Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases","volume":"32","author":"Tom\u00e1\u0161","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0345","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajh.2012.12","article-title":"Effect of 1-year anti-TNF-\u03b1 therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study","volume":"25","author":"Angel","year":"2012","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0350","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/rheumatology\/ker434","article-title":"Anti-TNF-\u03b1 therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up","volume":"51","author":"Capkin","year":"2012","journal-title":"Rheumatol. (Oxford)"},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0355","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3899\/jrheum.111073","article-title":"Evaluation of circulating endothelial and platelet microparticles in men with ankylosing spondylitis","volume":"39","author":"Sari","year":"2012","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0360","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/HYPERTENSIONAHA.109.143982","article-title":"Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study","volume":"55","author":"Angel","year":"2010","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.intimp.2022.109207_b0365","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1472-8206.2010.00872.x","article-title":"Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies","volume":"25","author":"Angel","year":"2011","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0370","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jbspin.2009.05.012","article-title":"Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis","volume":"77","author":"Mathieu","year":"2010","journal-title":"Joint Bone Spine."},{"issue":"7","key":"10.1016\/j.intimp.2022.109207_b0375","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10067-010-1388-4","article-title":"Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab","volume":"29","author":"Pieringer","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0380","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis","volume":"60","author":"van Eijk","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2022.109207_b0385","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.2007.086777","article-title":"Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade","volume":"68","author":"van Eijk","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0390","first-page":"292","article-title":"High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity","volume":"27","author":"Papadakis","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109207_b0395","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/rheumatology\/ken198","article-title":"Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease","volume":"47","author":"Mathieu","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0400","first-page":"580","article-title":"The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders","volume":"24","author":"Agirbasli","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109207_b0405","first-page":"2440","article-title":"Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab","volume":"33","author":"Spanakis","year":"2006","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0410","first-page":"921","article-title":"Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Kiortsis","year":"2006","journal-title":"J. Rheumatol."},{"issue":"36","key":"10.1016\/j.intimp.2022.109207_b0415","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.12998\/wjcc.v9.i36.11392","article-title":"Acute myocardial infarction in a young man with ankylosing spondylitis: a case report","volume":"9","author":"Wan","year":"2021","journal-title":"World J Clin Cases."},{"issue":"2","key":"10.1016\/j.intimp.2022.109207_b0420","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/1756-185X.12052","article-title":"Acute coronary syndrome caused by infliximab in a patient with ankylosing spondylitis","volume":"16","author":"Kumar","year":"2013","journal-title":"Int J Rheum Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109207_b0425","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10067-015-3134-4","article-title":"Etanercept treatment-related c-ANCA-associated large vessel vasculitis","volume":"35","author":"Ginsberg","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109207_b0430","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-224093","article-title":"Cardiac tamponade in a patient with ankylosing spondylitis: a notable response to TNF inhibitors","author":"Kwan","year":"2018","journal-title":"BMJ Case Rep."},{"issue":"7","key":"10.1016\/j.intimp.2022.109207_b0435","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1093\/rheumatology\/keab082","article-title":"Club Rhumatismes et Inflammations (CRI). TNF inhibitors for the management of inflammatory heart disease in spondyloarthritis: French multicentre case-series and literature review","volume":"60","author":"Tennenbaum","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.intimp.2022.109207_b0440","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/j.1756-185X.2011.01650.x","article-title":"Valvulitis and aortitis associated with ankylosing spondylitis: early detection and monitoring response to therapy using cardiac magnetic resonance imaging","volume":"14","author":"Looi","year":"2011","journal-title":"Int J Rheum Dis."},{"issue":"7","key":"10.1016\/j.intimp.2022.109207_b0445","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3899\/jrheum.160762","article-title":"Club Rhumatismes et Inflammations. Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases","volume":"44","author":"Rivi\u00e8re","year":"2017","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109207_b0450","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jbspin.2012.03.006","article-title":"Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit","volume":"79","author":"Verhoeven","year":"2012","journal-title":"Joint Bone Spine."},{"issue":"6","key":"10.1016\/j.intimp.2022.109207_b0455","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3899\/jrheum.110076","article-title":"Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of infliximab in a patient with ankylosing spondylitis","volume":"38","author":"Miki","year":"2011","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109207_b0460","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10067-013-2244-0","article-title":"Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature","volume":"32","author":"Hemmati","year":"2013","journal-title":"Clin. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:15Z","timestamp":1761587175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":92,"alternative-id":["S1567576922006919"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109207","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109207"}}